(VISA) and heterogeneous VISA (hVISA) isolates are considered to have emerged from VAN-susceptible S. aureus (VSSA) by spontaneous mutation during VAN exposure. We previously reported that laboratory mutant H14, obtained from VSSA strain ⌬IP by exposure to imipenem (IPM), showed overexpression of the vraSR two-component system and a typical hVISA phenotype. In the present study, to elucidate the mechanism of VSSA conversion to hVISA, we further characterized strain H14 by determining its whole-genome sequence, morphology, cell wall synthetic activity, and gene expression. Genome sequencing revealed that H14 harbored a mutated vraS (designated vraS H14 ) that caused an amino acid substitution (S 329 3L). This mutation is different from the VraS mutation (N 5 3I) identified in representative clinical hVISA strain Mu3. However, H14 exhibited a phenotype similar to that of Mu3, including heterogeneous resistance to VAN, enhanced cell wall synthetic activity, and vraSR overexpression. Replacement of the vraS gene of ⌬IP with the mutated vraS H14 gene confirmed that the S 329 3L substitution was responsible for both the upregulation of vraSR and conversion to the hVISA phenotype. This conversion was also achieved by using the vraS gene of Mu3, which carries a mutation (N 5 3I), but not with the native vraS gene of strain N315. Finally, we carried out a study to analyze the appearance of hVISA from VSSA by exposure of ⌬IP to selective concentrations of VAN and beta-lactam antibiotics. A total of 8 and 5 hVISA isolates were detected among 50 isolates selected with VAN and IPM, respectively. Among the 13 hVISA mutants, mutation in vraSR was detected only in mutant strain H14, suggesting that additional mutational mechanisms can be responsible for evolution to the hVISA phenotype. We conclude that exposure not only to VAN but also to beta-lactams may select for reduced glycopeptide susceptibility in S. aureus.
Methicillin (meticillin)-resistant Staphylococcus aureus (MRSA) is a major cause of serious nosocomial infections, and the emergence of virulent MRSA strains in the community is of particular concern (6) . Vancomycin (VAN) still serves as the main therapeutic agent for infections caused by multiresistant MRSA strains (17) . However, MRSA strains with various degrees of reduced susceptibility to glycopeptides, vancomycinintermediate S. aureus (VISA) and heterogeneous VISA (hVISA) strains, have emerged among multidrug-resistant MRSA clinical strains (9, 16) .
Recently, we identified several genes that are overexpressed in VISA strain Mu50 and hVISA Mu3 compared to their levels of expression in their isogenic VAN-susceptible S. aureus (VSSA) strain, strain Mu50⍀ (13) ; and among these, we found the overexpression of the vraSR two-component system (TCS), an upregulator of the S. aureus cell wall biosynthesis pathway (12, 13) . We also demonstrated that the vraS gene is overexpressed in ⌬IP-H14 (H14), a laboratory-derived hVISA strain obtained by selecting VSSA strain N315⌬IP (⌬IP) with 8 mg/liter of imipenem (IPM) (12) and showed that a single amino acid substitution in VraS was present in H14, Mu3, and Mu50 (10a).
In the study described here, we further characterized hVISA strain H14, investigated the role of the vraS mutation on the phenotype of H14, and evaluated the rates of selection of hVISA from VSSA ⌬IP following exposure to VAN and betalactam antibiotics.
MATERIALS AND METHODS
Bacterial strains, plasmids, and growth condition. The Staphylococcus strains and plasmids used in the present study are listed in Table 1 . The cloning and transformation of Escherichia coli JM109 were carried out by standard techniques (http://catalog.takara-bio.co.jp/en/PDFFiles/9052_e.pdf; Takara-Bio Co., Ltd., Shiga, Japan). All S. aureus strains were cultivated in brain heart infusion (BHI) broth or agar (Difco Laboratories, Detroit, MI) with aeration at 37°C, unless indicated otherwise. The antibiotics tetracycline and chloramphenicol (Sigma Chemical Co., St. Louis, MO) were used for the selection of the S. aureus transformants. VAN (Sigma) , teicoplanin (Astellas Pharma Inc., Osaka, Japan), ceftriaxone (CRO; Sigma), IPM (provided by Banyu Pharmaceutical Co., Tokyo, Japan), ampicillin-sulbactam (SAM; provided by Pfizer Pharmaceuticals Inc., Tokyo, Japan), and rifampin (RIF; rifampicin; Sigma) were used for antibiotic susceptibility tests. RIF-resistant (Rif r ) strain ⌬IP-rifR was selected by culturing ⌬IP on BHI agar containing 1 mg/liter of RIF and was obtained at a frequency of 2.8 ϫ 10
Ϫ7 . The isolates were evaluated for the presence of the His4813Tyr mutation in the rpoB gene of ⌬IP-rifR, which confers RIF resistance, by DNA sequencing, as reported previously (26) .
DNA methods. DNA manipulations were performed by standard methods (11) . Restriction enzymes were used as recommended by the manufacturer (Takara). Routine PCR amplification was performed with an Expand High Fidelity system (Roche, Mannheim, Germany).
Transmission electron microscopy. The preparation for and the examination of S. aureus cells by transmission electron microscopy were performed as described previously (4) .
Incorporation of 14 C-labeled D-glucose or 14 C-labeled N-acetyl-D-glucosamine into cells. The preparation of the cells and the purification of peptidoglycan were performed as described previously (8) , and the rate of incorporation was determined as described previously (8) . These assays were performed in triplicate.
Whole-genome sequencing of H14 and identification of SNPs compared to the sequence of parent strain ⌬IP. Sequencing of the strain H14 genome was performed with a Genome Sequencer 20 system, a recently introduced highly par-allel genome sequencer from 454 Life Sciences (Branford, CT). In a duplicate run with this instrument, 757,227 short reads, each of which had an average length of 108 bp, were collected. The short-read genome assembly generated by using the Genome Sequencer 20 system Assembler software contained 616 sequence contigs, including 95 contigs of Ͼ500 bp, for a total of 2,735,083 bp (average contig size, 28,790 bp). The chromosomal genome sequence of strain N315 (GenBank accession number BA000018) was used as a scaffold to assemble and orient the H14 contigs, and gap closing was carried out by long-range PCR primer walking. Sequencing of the PCR products was performed with a model 3730 capillary sequencer (Applied Biosystems Japan Ltd.). The resulting sequence of the H14 genome was then compared to that of N315, and the discovery of genome-wide single nucleotide polymorphisms (SNPs) was achieved by wholegenome alignments with the Mummer (version 3.20) software package (http: //mummer.sourceforge.net/). The discrepancies identified between the two genomes were then verified by resequencing of the corresponding loci of N315 and H14 genomic DNAs that were as long as the corresponding loci of ⌬IP, the parent strain of H14, with forward and reverse primers for each locus.
Construction of ⌬IP::vraS H14 strain. For the replacement of the serine amino acid residue with the leucine at position 329 in vraS of ⌬IP, we used the pKOR1 allele replacement system, as described previously (2) . In brief, a 1.0-kb vraS insert DNA encompassing 1-kb flanking sequences of phage attachment sites was generated by PCR from the chromosomal DNA of strain H14 by using the following primers: attB1-vraS (5Ј-GGGGACAAGTTTGTACAAAAAAGCAG GCTGTACTTACGTGAATGAAAAATCATATAAAGTTGAAAATAACAA T-3Ј) and attB2-vraS (5Ј-GGGGACCACTTTGTACAAGAAAGCTGGGTCA TGATCATCCACAAACAATACTTTAATCGTCATACGAATCCTC-3Ј). The PCR product was used for recombination with pKOR1, and then recombination products were transformed to E. coli DH5␣, according to the manufacturer's recommendations (Invitrogen, Carlsbad, CA). The resulting plasmid, pKOvraS H14 (where vraS H14 indicates the mutated vraS gene harbored by strain H14) was introduced into S. aureus ⌬IP by electroporation, generating transformant ⌬IP(pKO-vraS H14 ). Replacement of the vraS H14 gene allele with vraS in ⌬IP was carried out by a two-step procedure, as described previously (1, 2) . In this study, ⌬IP-rifR was also used for the construction of a vraS mutant. Because it became apparent by whole-genome sequence determination that the nucleotide sequences of ⌬IP and H14 did not differ except for the vraS mutation described above, it was necessary to introduce an artificial marker to exclude the unnoticed contamination of H14 in the culture of ⌬IP::vraS H14 . We utilized the amino acid substitution His4813Asn on rpoB, which confers RIF resistance, as a marker for mutant strain ⌬IP-rifR::vraS H14 in which the vraS gene was replaced by vraS H14 . In the final step of the procedure for mutant construction, 40 ⌬IP-rifR(pKOvraS H14 ) transformants were picked from tryptic soy agar plates containing 1 ng/liter of anhydrotetracycline, as described previously (1, 2) , from which we identified the desired strains in which the vraS gene was replaced by vraS H14 by determination of the nucleotide sequence.
Northern blot analysis. Preparation of total RNAs and Northern blot analysis
for vraS and vraR were performed as described previously (12) (20) . The vraSR probe was amplified by PCR with primers SR1 (5Ј-TCGATGAACCACTACA TTAGAACA-3Ј) and SR2 (5Ј-CTGCGAATCTTGAACCATTTTCTCT-3Ј) (see Fig. 3A) .
Antibiotic susceptibility tests. Antibiotic susceptibility was examined by Etest (AB Biodisk, Solna, Sweden) and population analysis, as described previously (9) . To detect hVISA strains among the 50 antibiotic-selected isolates, we determined the plating efficiency of each isolate on 4 mg/liter of VAN by population analysis. A VAN MIC of 4 mg/liter is the breakpoint for VISA (according to the criteria of the Clinical and Laboratory Standards Institute). hVISA status was defined for isolates that grew on VAN at 4 mg/liter at a frequency of greater than 10
Ϫ6 when a total of 10 8 cells was inoculated.
Statistical analysis. Two-by-two contingency tables were evaluated by Fisher's exact test. The statistical significance of the data was evaluated by Student's t test.
RESULTS AND DISCUSSION
Characterization of laboratory-derived hVISA mutant H14, which originated from VSSA strain ⌬IP. To investigate the phenotypes associated with reduced susceptibility to VAN, we analyzed the cell wall thickness and cell wall biosynthetic activity of H14, along with those of vraSR null mutant strain H14-KVR and parent strain ⌬IP, which were used as controls. Electron microscopy analysis showed that H14 had a significantly thicker cell wall and a rougher cell surface than ⌬IP, while H14-KVR had a cell wall much thinner than that of the parent strain (Fig. 1A ). Student's t test demonstrated that the increase in cell wall thickness was statistically significant in all cases (P Ͻ 0.0001).
To test for cell wall biosynthetic activity, the rates of incorporation of 14 C-labeled D-glucose and N-acetyl-D-glucosamine into the cell wall peptidoglycan fraction were evaluated by using a fixed number of nondividing cells. As shown in Fig. 1B , the incorporation of N-acetyl-D-glucosamine and D-glucose by H14 was significantly enhanced compared to that by ⌬IP and H14-KVR. These data indicate that the vraS mutation could cause enhanced cell wall biosynthesis activity. The vraS mutation is the only genetic event responsible for hVISA phenotype acquisition in H14. To clarify the genetic mechanism of hVISA phenotype acquisition, genome sequencing of H14 was carried out. The 2,795,992-bp-long whole-genome sequence of H14 was determined. Since H14 is an in vitro derivative of N315, the sequence was practically identical to that of N315 (14) , with the exceptions being 42 SNPs and 5 insertions or deletions between the two chromosomes (data not shown). PCR amplification and sequencing of ⌬IP chromosomal DNA for the 45 differences found no additional mutations except for the previously reported vraS mutation, which causes the replacement of a single amino acid, Ser 329 with Leu, in H14. This result confirms that the vraS mutation causing the replacement of Ser 329 with Leu was the only genetic event responsible for the acquisition of the hVISA phenotype in H14.
Phenotypic change conferred by vraS gene replacement. To see if the single amino acid substitution in the sequence encoding VraS H14 is responsible for both the phenotypic expression of hVISA and the overexpression of vraSR, we constructed two vraS mutants from ⌬IP and its RIF-resistant strain, ⌬IP-rifR. The native vraS gene of the parent strains was replaced by vraS H14 to obtain ⌬IP::vraS H14 and ⌬IP-rifR:: vraS H14 . Of 40 transformants analyzed, 3 (7.5%) were found to carry vraS H14 .
To evaluate the vraS H14 -mediated phenotypic conversion, we determined the VAN susceptibilities of ⌬IP::vraS H14 and ⌬IP-rifR::vraS H14 (vraS H14 mutant strains) by the Etest method and population analysis. As shown in Table 2 , the MICs of glycopeptides for the vraS H14 mutant were higher than those for the parent strain. The population analysis of ⌬IP::vraS H14 and ⌬IP-rifR::vraS H14 showed an increase in the proportion of VAN-resistant subpopulations compared with that for parent strain ⌬IP (Fig. 2) . The patterns of the population curves for H14 and ⌬IP::vraS H14 were almost superimposable on each other. The same result was obtained by using ⌬IP with the RIF resistance marker (the rpoB mutation), ex- cept that the population curve for ⌬IP-rifR::vraS H14 was slightly deflected with 4 mg/liter of VAN. These data clearly demonstrate that the vraS mutation alone can confer the phenotypic expression of heterogeneous VAN resistance.
The MICs were then determined, and the MICs of IPM, fosfomycin, bacitracin, and daptomycin for ⌬IP::vraS H14 and ⌬IP-rifR::vraS H14 were found to be increased compared with the MICs for ⌬IP for which the MICs were similar to those for H14 (Table 2) . Recently, Muthaiyan et al. reported that the inactivation of vraSR significantly increased susceptibility to daptomycin (18) . It was concluded that the vraS mutation (Ser3293Leu) alone was responsible for the altered antibiogram of H14 compared to that of its parent, strain ⌬IP.
Assessment of vraS activation among VISA strains carrying a mutation in the vraSR operon. By Northern blot analysis, we examined the transcriptional level of vraSR in the hVISA and VISA strains in which a single amino acid substitution in the vraSR operon has already been identified (12) . The positions of mutations in the vraSR operons of different strains are shown in Fig. 3A . Northern blot analysis demonstrated the overexpression of vraS in ⌬IP-rifR::vraS H14 , which was indistinguishable from the level of expression by original mutant strain H14 (Fig. 3B) . The fact that the whole genome of H14 has only a single mutation, in the vraS gene, compared to the sequence of ⌬IP suggests that the VraS H14 S3293L substitution (on the ATP-binding domain [amino acids 248 to 340]) affects the activation of the VraS sensor histidine kinase by modulating its autophosphorylation (3). The overexpression of vraS was also observed in VISA strains NJ and Mu50 and hVISA strain Mu3 (Fig. 3B) . The VraS A2603V substitution of NJ may also be associated with the activation of histidine kinase activity. These data are consistent with the findings of this study that implicate the increased expression of the vraSR system in the conversion of VSSA to hVISA. It has not previously been reported that amino acid mutations in a global regulator such as the vraSR TCS are involved in heterogeneous VAN resistance in S. aureus. Further investigation is needed to clarify the relationship between the function of TCS and the role of a mutation in vraS.
Recently, evidence of the evolution from hVISA to VISA in vivo during infection has been reported (5, 7, 21, 22, 24, 25) . However, the present study described for the first time that a mutation in vraS is responsible for the increased level of transcription of vraS and the phenotypic expression of hVISA by the gene replacement experiment. It was also confirmed that this mutation could cause cell wall thickening and increase the (Fig. 1B) . Although the location of the VraS mutation identified in H14 is different from that identified in clinical hVISA strain Mu3, both mutations had the same effect on conferring VAN resistance in gene replacement experiments (data not shown). Beta-lactam antibiotics can select hVISA mutants from VSSA strain ⌬IP. We exposed VSSA strain ⌬IP to selective concentrations of three beta-lactams, IPM, SAM, and CRO, to determine the ability to select mutants with reduced VAN susceptibility. ⌬IP is a derivative of N315 in which the mecI repressor was inactivated and from which the ␤-lactamasecarrying plasmid was cured ( Table 1 ). The genotype of inactivated mecI and the absence of the ␤-lactamase-carrying plasmid are characteristic of hVISA strain Mu3 and VISA strain Mu50, as reported previously (9) . Therefore, for this study we used ⌬IP as a representative Japanese health care-associated MRSA strain from which VISA has emerged. We spread 10 8 CFU from an overnight culture on BHI agar plates containing several concentrations of antibiotics. As a control for this assay, we also spread them onto the agar plate containing VAN. We then picked 50 putative mutant colonies from each plate containing a selective concentration of antibiotic (VAN, 2 mg/ liter; IPM, 8 mg/liter; SAM, 8 mg/liter; or CRO, 128 mg/liter) and established them as mutant strains by a colony purification procedure. A selective concentration was defined as the concentration which resulted in a reduction of the initial bacterial population by approximately 6 log units (with VAN) or 4 log units (with IPM, CRO, and SAM) (Fig. 4) .
To detect the presence of hVISA isolates among the selected isolates, all isolates were investigated for their VAN susceptibilities by population analysis. Eight and 5 hVISA isolatess were obtained from among the 50 isolates selected with VAN and IPM, respectively. No hVISA isolate was detected among the isolates selected with CRO or SAM. The rates of appearance of hVISA isolates among the 50 isolates selected with VAN and IPM isolates were 3.6 ϫ 10 Ϫ7 and 2.0 ϫ 10
Ϫ5
, respectively. We determined the nucleotide sequence of vraSR from 13 hVISA isolates, and a mutation was only in mutant strain H14. This suggests that different genetic mechanisms, other than The vraSR probes used for Northern blotting analysis are illustrated by lines. The probe was amplified by PCR with the primers (short arrows) described in Materials and Methods. The arrows below the genes indicate the direction of transcription. The VraS histidine kinase has two amino-terminal transmembrane domains, located between residues 7 and 25 and between residues 49 and 67, as determined by the use of von Heijne's algorithm. The VraS kinase orthologs are similar in domain organization and contain a PAS (period clock protein, aryl hydrocarbon receptor nuclear translocator, and single-minded protein) family domain which has signaling modules essentially found in proteins involved with signal transduction. A major transcription start codon located in the 133 bp upstream of SA1703 is indicated by a thin arrow above SA1703 (27) . The position of a single amino acid substitution in VraS in each VISA strain is shown on the map (10a, 19) . (B) Northern blot analysis of vraSR in ⌬IP, its derivative strains, hVISA strains, and VISA strains with a vraSR-specific DNA probe. Ethidium bromide staining of total RNA was used to demonstrate the equivalent loading of RNA. All strains were grown under noninducing conditions.
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on June 28, 2017 by guest http://aac.asm.org/ vraS mutations, are used to acquire hVISA phenotypic expression. From these results, we also confirmed that hVISA can be selected not only by VAN but also by IPM. Since IPM was frequently used for the treatment of MRSA infections before the clinical introduction of VAN in 1991 in Japan, we suspect a possible role of IPM in the early emergence of hVISA in Japan, ahead of its emergence in other countries in 1996.
